Streetbeat News

Regulatory

HALO

Halozyme Therapeutics, Inc. announced that argenx has received approval from the European Commission for VYVGART SC, a subcutaneous treatment for Generalized Myasthenia Gravis, which uses Halozyme's ENHANZE drug delivery technology.

Portfolio Pulse from Benzinga Newsdesk

November 16, 2023 | 2:05 pm

BLK

BlackRock (NYSE:BLK) has filed an S-1 form with the SEC to launch a spot Ether ETF, leading to a 2% surge in Ether's price. The firm also registered 'iShares Ethereum Trust' in Delaware, indicating a growing focus on cryptocurrency. BlackRock's move could increase mainstream adoption and market stability for cryptocurrencies, as it follows a trend of positive market reactions to ETF-related news and a shift in CEO Larry Fink's stance from skepticism to support.

Portfolio Pulse from Murtuza Merchant

November 16, 2023 | 1:50 pm

BCAN

BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) has submitted a plan for developing CRM software with AI for the medical cannabis industry, with a budget of $1.5M and a potential grant of $0.75M from Israel's Innovation Authority. The Israeli Finance Ministry has increased the high-tech sector fund to $100M to support startups during wartime challenges. The high-tech sector is vital to Israel's economy, contributing 18% to the GDP and 50% to foreign exports. The grant decision is pending, and there is no assurance of its full amount being awarded.

Portfolio Pulse from Benzinga Newsdesk

November 16, 2023 | 1:47 pm

AMD

ASML

AVGO

EPHE

INTC

LRCX

NVDA

NXPI

QCOM

RMBS

SPY

TSM

The U.S. has announced a new partnership with the Philippines aimed at exploring opportunities within the semiconductor supply chain, according to a statement cited by Reuters. This move is part of broader efforts to secure the semiconductor supply chain amid global shortages and geopolitical tensions.

Portfolio Pulse from Benzinga Newsdesk

November 16, 2023 | 1:47 pm

SOUN

SoundHound AI Inc (NASDAQ:SOUN) shares dropped after the company announced it could not file its quarterly report for Q3 due to immaterial accounting errors related to historical financing transactions. The company also expects to report material weaknesses in its internal control over financial reporting. This follows a recent rally where the stock rose approximately 28% after preliminary Q3 results beat estimates.

Portfolio Pulse from Adam Eckert

November 16, 2023 | 1:40 pm

GURE

Gulf Resources, Inc. (NASDAQ:GURE) announced upcoming management changes, with Chairman Min Yang and board member Tengfei Zhang not standing for re-election at the Annual Meeting on November 30, 2023. CEO Xiaobin Liu will become the new Chairman. The company has nominated a new director candidate, details of which are in the proxy statement filed on October 3, 2023. Yang expressed pride in the team and believes it's the right time to focus on other business pursuits, while Liu thanked Yang for his mentorship.

Portfolio Pulse from Benzinga Newsdesk

November 16, 2023 | 1:36 pm

APLM

Apollomics Inc. announced that its Chinese partner, Avistone Biotechnology, received approval from the NMPA to commercialize vebreltinib for MET exon 14 skipping NSCLC in China. Apollomics is in discussions with the FDA for a New Drug Application in the U.S. based on clinical data from the SPARTA trial and Avistone's KUNPENG trial. NSCLC, which accounts for 85% of lung cancer cases, has limited treatment options for patients with MET exon 14 skipping mutations. Apollomics retains rights to vebreltinib outside China, Hong Kong, and Macau.

Portfolio Pulse from Benzinga Newsdesk

November 16, 2023 | 1:34 pm

ADN

Advent Technologies received a letter from the Greek State confirming continued support for the Green HiPo Project, with an updated funding plan of EUR 60 million. The Just Transition Fund will provide a grant of EUR 24 million, which is 40% of the total budget, to initiate the project.

Portfolio Pulse from Benzinga Newsdesk

November 16, 2023 | 1:17 pm

CRSP

VRTX

The UK MHRA has granted conditional marketing authorization for Casgevy, a CRISPR/Cas9 gene-edited therapy for SCD and TDT, developed by Vertex Pharmaceuticals and CRISPR Therapeutics. The therapy has shown positive trial results and could replace bone marrow transplants, but it requires a complex administration process. VRTX shares closed at $349.34, and CRSP shares are up 4.93% in premarket trading.

Portfolio Pulse from Vandana Singh

November 16, 2023 | 1:17 pm

CATX

Perspective Therapeutics has completed the dosing for Cohort 1 in its Phase 1/2A trial of [212Pb]VMT-α-NET, a treatment for patients with unresectable or metastatic somatostatin receptor type 2-expressing neuroendocrine tumors.

Portfolio Pulse from Benzinga Newsdesk

November 16, 2023 | 1:14 pm